HLK Pharmaceuticals


HLK Pharma, established in 2016, is an innovative pharmaceutical company focused on high-end formulation research and development. With a core team of renowned scientists and experts from the US, the company specializes in the development and industrialization of differentiated 'innovative drugs + modified innovative drugs'. It leverages advanced platform technologies and a cross-border development platform to create best-in-class new drugs, aiming to improve patient outcomes and promote health globally. The company emphasizes clinical needs and technological innovation, with a strong technical advantage in poorly soluble drug oral formulations, and aims to develop international standards of new drugs and reformulated drugs in fields such as oncology, neurological, immune, and allergic diseases.

Industries

biotechnology
life-science
pharmaceutical

Nr. of Employees

small (1-50)

HLK Pharmaceuticals

New Haven, Connecticut, United States, North America


Products

Clinical-stage formulation-enabled drug candidates

A portfolio of internally developed and partnered drug candidates across oncology, neurology, immunology and allergy that have been advanced using formulation platforms to clinical stages.


Services

Formulation development (preclinical to clinical)

End-to-end formulation services including preformulation, prototype development, biopharmaceutics optimization and scale-up for clinical supply.

CMC development and technology transfer

CMC strategy development, process optimization and technology transfer to manufacturing partners for clinical and commercial production.

Novel delivery system development (peptides, oligonucleotides, conjugates)

Design and development of delivery strategies for peptides, siRNA/oligonucleotides and conjugated small molecules across multiple administration routes.

Regulatory strategy and filing support (including 505(b)(2))

Regulatory planning and support for filings aligned to US and China standards, including development strategies suitable for 505(b)(2) pathway submissions.

Technology licensing and partnering

Licensing of formulation platforms and partnership development for CMC projects and commercialization in APAC/global markets.

Preclinical ADME and DDI assessment support

Support for pharmacokinetics, drug metabolism and drug–drug interaction studies, including microbiome-related disposition assessment to guide development decisions.

Expertise Areas

  • Formulation development for poorly soluble drugs
  • Oral drug delivery and lipid-based delivery systems
  • Controlled-release and modified-release formulations
  • Delivery technologies for peptides and oligonucleotides
  • Show More (5)

Key Technologies

  • Spray-drying for amorphous solid dispersions
  • Hot-melt extrusion
  • Self-emulsifying drug delivery systems (SEDDS)
  • Nano-milling / nanogrinding
  • Show More (6)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.